Avicanna Revenue and Competitors

Toronto, ON CAN

Location

$30.8M

Total Funding

Cannabis

Industry

Estimated Revenue & Valuation

  • Avicanna's estimated annual revenue is currently $20.5M per year.(i)
  • Avicanna's estimated revenue per employee is $270,000
  • Avicanna's total funding is $30.8M.

Employee Data

  • Avicanna has 76 Employees.(i)
  • Avicanna grew their employee count by -12% last year.

Avicanna's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Medical ProgramsReveal Email/Phone
3
VP, CommercializationReveal Email/Phone
4
VP Scientific AffairsReveal Email/Phone
5
EVP MarketingReveal Email/Phone
6
VP Finance & BI - Latam OperationsReveal Email/Phone
7
VP Commercial Operations Europe / LATAMReveal Email/Phone
8
VP Business Development & Managing Director AureusReveal Email/Phone
9
Director Business Intelligence & AnalyticsReveal Email/Phone
10
Director ProcurementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.4M53-59%$9.2MN/A
#2
$149.5M4437%N/AN/A
#3
$153.6M4552%N/AN/A
#4
$10.6M499%N/AN/A
#5
N/A0N/A$7.7MN/A
#6
$3.8M205%N/AN/A
#7
$144.1M4275%N/AN/A
#8
$21.1M78-20%N/AN/A
#9
$568.6M1116-17%$4.5BN/A
#10
$65.6M2213%N/AN/A
Add Company

What Is Avicanna?

Avicanna aims to establish itself as a leader in the global medical cannabis industry through its product discovery and development processes, intellectual property portfolio, strategic relationships, and cultivation infrastructure. Avicanna believes that its two main business segments, namely research and development or "R&D"​ and cultivation, strategically position it to be a front runner in the development, manufacturing and commercialization of plant-derived cannabinoid-based products and Extracts throughout North America, Latin America, Europe and Asia. It intends to capitalize on the nexus between both business segments where the intellectual property gained from its R&D efforts is used to inform and improve the products of its cultivation and extraction activities and the raw materials from its cultivation and extraction efforts can be used to further its R&D activities; and Avicanna anticipates, in both cases, to benefit from a reduced cost from what would be incurred through purchasing such intellectual property or raw materials, as the case may be, from third parties. Avicanna is growing its network of strategic relationships with institutions they believe to be best-in-class and market leading, located around the world to assist with the achievement of its business objectives, including large-scale, environmentally sustainable cultivation, scientific R&D, and manufacturing and distribution.

keywords:N/A

$30.8M

Total Funding

76

Number of Employees

$20.5M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Avicanna News

2022-04-17 - EXCLUSIVE: How Avicanna Is Advancing Plant-Derived, Cannabinoid-Based Products - Benzinga

Avicanna supplies its own cosmetic, medical and pharmaceutical products with a high-quality API through its sustainable cultivation operation in...

2022-04-13 - Avicanna Enters into Exclusive License and Supply ...

The intellectual property related to Avicanna's proprietary cannabinoid-based pharmaceutical preparations was originally developed through the...

2022-03-30 - Avicanna Announces Filing of Annual Financial Statements for ...

Avicanna is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16M7613%N/A
#2
$7.8M767%N/A
#3
$11M761%N/A
#4
$17.3M769%N/A
#5
$15.6M761%N/A